Consensus Target
High Target
Median Target
Low Target
| Date | Analyst | Company | Price Target | News Title |
|---|---|---|---|---|
| 2024-09-23 | Graig Suvannavejh | Mizuho Securities | $1 | Mizuho Reiterates Neutral Rating on BioXcel Therapeutics (BTAI) |
| 2024-04-15 | Raghuram Selvaraju | H.C. Wainwright | $10 | BioXcel Therapeutics (BTAI) PT Lowered to $10 at H.C. Wainwright |
| 2023-08-15 | Graig Suvannavejh | Mizuho Securities | $4 | Challenging Horizon For BioXcel: Analysts Dive Into Igalmi's Potential And Resh… |
| 2023-01-03 | N/A | H.C. Wainwright | $73 | HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target … |
| 2022-11-11 | N/A | Guggenheim | $25 | Guggenheim Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $25 |